巨噬细胞移动抑制因子表达在癌症患者中的预后意义：一项系统评价与荟萃分析

Prognostic significance of macrophage migration inhibitory factor expression in cancer patients: A systematic review and meta-analysis.

作者信息

Koh Hyun Min, Kim Dong Chul

机构信息

Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon.

Department of Pathology, Gyeongsang National University School of Medicine.

出版信息

Medicine (Baltimore). 2020 Aug 7;99(32):e21575. doi: 10.1097/MD.0000000000021575.

BACKGROUND

Recent studies showed that Macrophage migration inhibitory factor (MIF) is overexpressed and closely associated with prognosis in cancer patients. The present study was systematically evaluated the prognostic significance of MIF expression in cancer patients.

METHODS

PubMed, Cochrane library and Scopus were searched for eligible studies up to January 2020. Pooled hazard ratio with confidence interval (CI) was determined to assess the relationship between MIF expression and survival in cancer patients.

RESULTS

A total of 8 studies comprising 847 cancer patients were included in this meta-analysis. For overall survival, the pooled hazard ratio was 2.23 (95% CI 1.67-2.99, P < .001). For disease-free survival, the pooled hazard ratio was 2.24 (95% CI 1.69-2.96, P < .001). The results suggested that high expression of MIF was significantly related to poor overall survival and disease-free survival in cancer patients.

CONCLUSION

MIF expression could be a valuable prognostic factor in cancer patients.

背景

近期研究表明，巨噬细胞移动抑制因子（MIF）在癌症患者中过度表达，且与预后密切相关。本研究系统评估了MIF表达在癌症患者中的预后意义。

方法

检索了截至2020年1月的PubMed、Cochrane图书馆和Scopus数据库中的相关研究。通过计算合并风险比及置信区间（CI）来评估MIF表达与癌症患者生存率之间的关系。

结果

本荟萃分析共纳入8项研究，涉及847例癌症患者。对于总生存期，合并风险比为2.23（95%CI 1.67 - 2.99，P < 0.001）。对于无病生存期，合并风险比为2.24（95%CI 1.69 - 2.96，P < 0.001）。结果表明，MIF高表达与癌症患者较差的总生存期和无病生存期显著相关。